The trajectory of the erectile dysfunction drug presents a complex picture for investors. While the initial introduction generated significant returns, the end of its exclusive rights opened the avenue to off-brand https://socialtechnet.com/story7226179/the-copyright-and-pharma-a-precarious-investment